Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 6/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | NMT1 | P30419 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 4/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452622 | 0.92 | MAPK1 (0.45) | IKBKBCHUKMAPK10FYNMKNK1 | |
| SCHEMBL12699506 | 0.90 | NMT1 (0.47) | IKBKBPIM1NMT1SIGMAR1FYN | |
| SCHEMBL12699333 | 0.89 | PIM1 (0.56) | PIM1SIGMAR1FYN | |
| SCHEMBL3452219 | 0.83 | NMT1 (0.48) | NMT1FYNMKNK1 | |
| SCHEMBL3452045 | 0.82 | PIM1 (0.49) | PIM1SIGMAR1FYNMKNK1 | |
| SCHEMBL3646812 | 0.80 | MKNK1 (0.61) | IKBKBPIM1CHUKMAPK10ACHE | |
| SCHEMBL2946558 | 0.79 | MKNK1 (0.61) | FYNMKNK1 | |
| SCHEMBL15254301 | 0.79 | IRAK4 (0.45) | IKBKBFYNMKNK1 | |
| SCHEMBL3452185 | 0.79 | FYN (0.61) | PIM1FYNMKNK1 | |
| SCHEMBL3041634 | 0.78 | FYN (0.67) | IKBKBPIM1CHUKMAPK10FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012127212-A1 | IMIDAZO [1, 2 - B] PYRIDAZINE DERIVATIVES AS CDPK1 INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-09-27 | — | — | WO | disclosed |